Yahoo•2026-04-18
Envista, Baxter, Surgery Partners, Charles River Laboratories, and Repligen Stocks Trade Up, What You Need To KnowNVST — Envista Holdings Corp
NYSE · Health Care · Health Care
$27.20+23.08%Market cap4.28B
- Latest Close
- $27.2
- 30-Day Move
- +23.1%
- Market Cap
- $4.3B
- Shares Outstanding
- 163,880,000
- P/E Ratio
- 91.14
- P/B Ratio
- 1.15
Analyst consensus: Buy · 20 analysts
NYSE:NVSTHealth Care / Health CareDelayed public snapshot
Envista Holdings Corp
A read-only Alphactor snapshot forEnvista Holdings Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$27.2
30-Day Move
+23.1%
Market Cap
$4.3B
Shares Outstanding
163,880,000
P/E Ratio
91.14
P/B Ratio
1.15
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$27.20
+23.1%last 90 delayed daily bars
Market cap$4.3B
90D High
$30.42
90D Low
$20.73
Avg Volume
2,678,870
What stands out
Gross margin is running at 55.0%, which gives a quick read on operating quality before you open the full model.
Net margin is 1.7%, useful for comparing NVST against peers in Health Care.
NVST is up 23.1% over the last 30 trading days shown on this page.
Latest operating income is $236M, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$36.93
Rule of 40
16.8%
Dark Pool Short %
87.0%
Fundamentals snapshot
Latest Close
$27.2
30-Day Move
+23.1%
Market Cap
$4.3B
Shares Outstanding
163,880,000
P/E Ratio
91.14
P/B Ratio
1.15
ROE
1.5%
ROA
83.0%
Gross Margin
55.0%
Operating Margin
8.0%
Net Margin
1.7%
Debt / Equity
0.47
Current Ratio
2.38
Latest Revenue
$2.7B
Financial statement snapshot
Revenue
$2.7B
Gross Profit
$1.5B
Operating Income
$236M
Net Income
$47M
Gross Margin
5502.0%
Net Margin
173.0%
Current Ratio
2.38
Debt / Equity
0.47
Valuation snapshot
Fair Value
$36.93
Upside / Downside
+35.8%
Signal
Undervalued
Implied Growth
6.4%
DCF
$18.04
EPV
$12.12
EV/Rev
$80.62
Growth Assumption
1.9%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$230M
Valuation spread
Current Price
$27.20
Composite Fair Value
$36.93
DCF
$18.04
EPV
$12.12
EV/Rev
$80.62
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
1.75
Distress
Piotroski
7
Strong (7-9)
Cash Conversion
5.87x
Rule of 40
16.8%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $2.6B | $343M | $243M | $107M |
| 2023-12-31 | $2.6B | $315M | $-100M | $218M |
| 2024-12-31 | $2.5B | $137M | $-1.1B | $303M |
| 2025-12-31 | $2.7B | $236M | $47M | $230M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Yahoo•2026-04-16
Greater Canal Efficiency. Less Waste. Introducing ZenSeal(TM) Pro with ZenSave(TM) Tips from Kerr DentalYahoo•2026-04-16
Kerr Dental Launches Demi(TM) Pro - The Light That Moves With YouYahoo•2026-04-16
Abbott (ABT) Beats Q1 Earnings and Revenue EstimatesFintel•2026-04-16
Citigroup Initiates Coverage of Envista Holdings (NVST) with Neutral RecommendationAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Eaton Vance Growth Trust-Eaton Vance Atlanta Capital SMID-Cap Fund | 5,339,537 | 0.03% | 2025-12-31 |
| iShares Trust-iShares Core S&P Mid-Cap ETF | 5,315,883 | 0.03% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 5,246,617 | 0.03% | 2025-12-31 |
| Ariel Investment Trust-Ariel Fund | 5,084,223 | 0.03% | 2025-12-31 |
| Franklin Value Investors Trust-FRANKLIN SMALL CAP VALUE FUND | 4,464,269 | 0.03% | 2026-01-31 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 3,729,923 | 0.02% | 2025-12-31 |
| UNDISCOVERED MANAGERS Fd.S-Undiscovered Managers Behavioral Value Fd. | 3,233,901 | 0.02% | 2025-12-31 |
| Victory Portfolios-Victory Sycamore Small Company Opportunity Fund | 2,750,000 | 0.02% | 2025-12-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
BlackRock
Filed 2024-05-10
$443M
--
Vanguard Group
Filed 2026-01-29
$349M
-1.8%
Geode Capital Management
Filed 2026-02-09
$67M
-1.3%
Charles Schwab
Filed 2026-02-13
$46M
-3.1%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
3.95
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
20
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.